Medical students are digital, but not necessarily mobile

Share this article:

Compas's May white paper about a migration to digital over print got some added ballast from a September study released by Athenahealth about the new wave of medical professionals. In short: medical students are digital, but like other trends we've seen among HCPs, digital does not always have to mean mobile.

Among the findings: 66% use digital clinical references as a go-to, but only 35% of those same doctors will make their first digital search through a mobile device. Significantly lagging: relying on peers. Just 21% of the surveyed medical students said their first stop for clinical information would be a colleague or professor. Tablets are also being used by around 54% of the surveyed medical students, a number that needs a bit of qualification, in that 18% of that group are required to use tablets, while 82% use them because they want to.

These findings track with an earlier ePocrates mobile trends report that that found clinicians rely heavily on mobile devices for clinical information and contacting colleagues, with smartphones edging out tablets, and desktops remaining a foundational digital resource.

Medical students also indicated a strong sense of what was an appropriate use of technology between HCPs and patients: 82% said they would recommend apps to patients, but 91% said it was unacceptable to friend a patient on Facebook.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...